Another lame attempt by you at diversion and obfuscation—this time with drivel about broken glass and such.
You cannot will away program-survival bias by labeling it as trivial. To the contrary, understanding program-survival bias is an absolutely critical element to biotech investing. If you don’t get it, you will be doomed to overestimating the chances of clinical success in pivotal trials over and over again.
News 
Market Data 
Discover 
